Summary
Boston Scientific Corporation (BSX) reported strong net sales growth of 8.6% for fiscal year 2018, reaching $9.823 billion. This growth was driven by an 8.0% operational increase, supplemented by favorable foreign currency fluctuations. The company's strategy focuses on strengthening category leadership, expanding into high-growth adjacencies, driving global expansion, and developing key capabilities. Key product areas contributing to this performance include Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, and Urology and Pelvic Health, with notable growth in structural heart therapies and neuromodulation. The company completed several strategic acquisitions in 2018, including Augmenix, Claret Medical, and NxThera, to enhance its product portfolio and market position. Financially, Boston Scientific reported a significant increase in net income to $1.671 billion ($1.19 per diluted share) in 2018, compared to $104 million ($0.08 per diluted share) in 2017. This improvement was supported by operational growth and a reduction in certain charges, though the company also noted significant investments in research and development and ongoing restructuring initiatives. Looking ahead, the company is pursuing the acquisition of BTG plc, expected to close in the first half of 2019, which is anticipated to further bolster its offerings in minimally invasive procedures for cancer and vascular diseases.
Financial Highlights
54 data points| Revenue | $9.82B |
| Cost of Revenue | $2.81B |
| Gross Profit | $7.01B |
| SG&A Expenses | $3.57B |
| Operating Expenses | $5.50B |
| Operating Income | $1.51B |
| Interest Expense | $241.00M |
| Net Income | $1.67B |
| EPS (Basic) | $1.21 |
| EPS (Diluted) | $1.19 |
| Shares Outstanding (Basic) | 1.38B |
| Shares Outstanding (Diluted) | 1.40B |
Key Highlights
- 1Net sales increased by 8.6% to $9.823 billion in 2018, driven by strong operational performance.
- 2Net income rose significantly to $1.671 billion ($1.19 per diluted share) in 2018, a substantial increase from $104 million ($0.08 per diluted share) in 2017.
- 3The company completed several strategic acquisitions in 2018, including Augmenix, Claret Medical, NxThera, and nVision Medical, to expand its product portfolio.
- 4Neuromodulation sales saw a notable increase of 22.7%, driven by the launch of Spectra WaveWriter and Vercise DBS Systems.
- 5The proposed acquisition of BTG plc was announced, aiming to strengthen Boston Scientific's position in interventional oncology and vascular diseases.
- 6Despite strong sales growth, the company maintains a focus on cost management through ongoing restructuring initiatives.
- 7International sales represented 44% of total net sales in 2018, highlighting the company's global reach.